Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

Overview of attention for article published in Journal of Asthma and Allergy, October 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 5,875 followers.

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. https://t.co/AQKj28elXh

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. https://t.co/1Jdu8fhK5Y